Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disorders

A method of treating nonalcoholic steatohepatitis in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of (i) a deuterium-enriched compound of Formula I, or a pharmaceutically acceptable salt thereof, having an optical purity of at least 75% enantiomeric excess;

• and (ii) a second therapeutic agent, to treat the nonalcoholic steatohepatitis, wherein the compound of Formula I is represented by:
• wherein:
• A1, A2, A3, and A4 are independently -C(R9)(R10)-;
• A5 is -C(R11)(R12)(R13);
• R1, R2, R3, R4, R5, R6, R7, and R8 are independently H or D;
• R9, R10, R11, R12, and R13 each represent independently for each occurrence H or D;
• and
• Z is H or D, provided that the abundance of deuterium in Z is at least 30%.

A method of treating liver cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of (i) a deuterium-enriched compound of Formula I, or a pharmaceutically acceptable salt thereof, having an optical purity of at least 75% enantiomeric excess;

• and (ii) a second therapeutic agent, to treat the liver cancer, wherein the compound of Formula I is represented by:
• wherein:
• A1, A2, A3, and A4 are independently -C(R9)(R10)-;
• A5 is -C(R11)(R12)(R13);
• R1, R2, R3, R4, R5, R6, R7, and R8 are independently H or D;
• R9, R10, R11, R12, and R13 each represent independently for each occurrence H or D;
• and
• Z is H or D, provided that the abundance of deuterium in Z is at least 30%.